Blood Pressure-Lowering Peptides Discovered in Green Coffee Beans
Researchers identified two novel peptides from green coffee bean protein that inhibit the ACE enzyme — the same target as common blood pressure medications — with IC50 values of 57.54 and 40.37 μM.
Quick Facts
What This Study Found
Two novel peptides, IIPNEVY and ITPPVMLPP, were identified from green coffee bean protein hydrolysates with ACE inhibitory IC50 values of 57.54 and 40.37 μM, respectively. Molecular docking revealed both peptides bind near the S1 active pocket of ACE to form stable enzyme-peptide complexes.
The peptides work through different inhibition mechanisms: IIPNEVY acts as a noncompetitive inhibitor (binding to the enzyme at a site separate from the substrate), while ITPPVMLPP is a mixed-type inhibitor (can bind both the free enzyme and the enzyme-substrate complex). Five candidate peptides were initially identified through in silico screening, with these two showing the strongest activity in vitro.
Key Numbers
How They Did This
Green coffee bean proteins were extracted and digested using two enzymes (alcalase and thermolysin) to produce peptide fragments. The resulting peptides were identified using liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS). Computer-based (in silico) screening predicted which peptides might inhibit ACE. The top candidates were then tested in vitro for ACE inhibition, and molecular docking was used to model how the peptides interact with the enzyme. Inhibition kinetics were determined using Lineweaver-Burk plots.
Why This Research Matters
ACE inhibitors are one of the most widely prescribed drug classes for high blood pressure. Finding natural food-derived peptides that block the same enzyme could lead to functional foods or nutraceuticals for blood pressure management with potentially fewer side effects than pharmaceutical ACE inhibitors. Coffee is one of the most consumed beverages globally, making coffee-derived bioactive peptides particularly interesting from a dietary perspective.
The Bigger Picture
Food-derived ACE inhibitory peptides have been an active research area for decades, with peptides from milk (lactotripeptides IPP and VPP), fish, and soy already reaching the supplement market. Coffee-derived peptides add to this growing library of natural bioactive peptides. The combination of in silico prediction with in vitro validation represents the modern approach to bioactive peptide discovery — using computational tools to narrow down candidates before lab testing, which dramatically speeds up the process.
What This Study Doesn't Tell Us
This is entirely an in silico and in vitro study — no animal or human testing was conducted. The IC50 values in the micromolar range are relatively modest compared to pharmaceutical ACE inhibitors. It's unknown whether these peptides would survive digestion intact or be absorbed into the bloodstream at active concentrations. The amount of these peptides in a typical cup of coffee is likely negligible, and concentrated supplementation would be needed for any blood pressure effect.
Questions This Raises
- ?Can these coffee-derived peptides survive gastrointestinal digestion and reach the bloodstream at concentrations sufficient to inhibit ACE?
- ?How do these peptides compare in potency to established food-derived ACE inhibitors like the milk-derived lactotripeptides IPP and VPP?
Trust & Context
- Key Stat:
- IC50 = 40.37 μM The most potent coffee peptide (ITPPVMLPP) inhibited ACE at micromolar concentrations through a mixed-type inhibition mechanism
- Evidence Grade:
- This is a discovery-phase study using computational and in vitro methods only. While it identifies promising peptide candidates, no animal or human data exists. The findings represent the earliest stage of bioactive peptide research.
- Study Age:
- Published in 2023, this study uses current computational peptide discovery methods. The ACE inhibitory peptide field is mature, but coffee-derived candidates are relatively new additions.
- Original Title:
- Discovery of ACE Inhibitory Peptides Derived from Green Coffee Using In Silico and In Vitro Methods.
- Published In:
- Foods (Basel, Switzerland), 12(18) (2023)
- Authors:
- Dai, Haopeng, He, Min, Hu, Guilin, Li, Zhongrong, Al-Romaima, Abdulbaset, Wu, Zhouwei, Liu, Xiaocui, Qiu, Minghua
- Database ID:
- RPEP-06820
Evidence Hierarchy
Frequently Asked Questions
Could drinking coffee lower blood pressure through these peptides?
It's extremely unlikely that a normal cup of coffee contains enough of these specific peptides to affect blood pressure. The peptides were isolated from green (unroasted) coffee bean protein using industrial enzymes, a process very different from brewing coffee. Any practical application would require concentrated peptide preparations, not regular coffee consumption.
How do these peptides compare to ACE inhibitor drugs like lisinopril?
Pharmaceutical ACE inhibitors are far more potent — lisinopril has an IC50 in the low nanomolar range, roughly 1,000 times more potent than these coffee peptides. However, food-derived ACE inhibitory peptides are being studied as gentler, preventive approaches rather than replacements for prescription medications, potentially useful as functional food ingredients for people with mildly elevated blood pressure.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-06820APA
Dai, Haopeng; He, Min; Hu, Guilin; Li, Zhongrong; Al-Romaima, Abdulbaset; Wu, Zhouwei; Liu, Xiaocui; Qiu, Minghua. (2023). Discovery of ACE Inhibitory Peptides Derived from Green Coffee Using In Silico and In Vitro Methods.. Foods (Basel, Switzerland), 12(18). https://doi.org/10.3390/foods12183480
MLA
Dai, Haopeng, et al. "Discovery of ACE Inhibitory Peptides Derived from Green Coffee Using In Silico and In Vitro Methods.." Foods (Basel, 2023. https://doi.org/10.3390/foods12183480
RethinkPeptides
RethinkPeptides Research Database. "Discovery of ACE Inhibitory Peptides Derived from Green Coff..." RPEP-06820. Retrieved from https://rethinkpeptides.com/research/dai-2023-discovery-of-ace-inhibitory
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.